{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 1575,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019dd923-5e88-73ef-bd5a-28c72cc9d740",
      "docSlug": "1b9c53be021f8188",
      "documentTitle": "asset and wealth management mn",
      "authorId": "GoldmanSachs",
      "authorName": "Goldman Sachs",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "portrait",
      "aspectRatio": 0.773,
      "pageNumber": 181,
      "slideType": "appendix_disclosure",
      "function": "other",
      "notes": "This is a standard regulatory disclosure document.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-28c72cc9d740/181",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-28c72cc9d740",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-28c72cc9d740#slide-181",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-28c72cc9d740",
      "docSlug": "1b9c53be021f8188",
      "documentTitle": "asset and wealth management mn",
      "authorId": "GoldmanSachs",
      "authorName": "Goldman Sachs",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "portrait",
      "aspectRatio": 0.773,
      "pageNumber": 182,
      "slideType": "appendix_disclosure",
      "function": "appendix",
      "notes": "This is a standard legal disclosure page from an ERISA or investment advisory presentation.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-28c72cc9d740/182",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-28c72cc9d740",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-28c72cc9d740#slide-182",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-28c72cc9d740",
      "docSlug": "1b9c53be021f8188",
      "documentTitle": "asset and wealth management mn",
      "authorId": "GoldmanSachs",
      "authorName": "Goldman Sachs",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "portrait",
      "aspectRatio": 0.773,
      "pageNumber": 183,
      "slideType": "appendix_disclosure",
      "function": "other",
      "notes": "This is a standard legal disclosure page, likely part of a larger document set.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-28c72cc9d740/183",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-28c72cc9d740",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-28c72cc9d740#slide-183",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": "https://imgproxy.kitesheet.com/hVoscs9elBj8V6pU1v-pGnXiI1AO1pvLRq9SJdFHbGA/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82ZDM1NDVhNmMwMTBkN2NiL3AwMDEuanBn",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/1",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": "https://imgproxy.kitesheet.com/caSPpgyY1Xy-eg-0TJd7zXDtcH0Ck7K7j3pE-HQGZ1o/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82ZDM1NDVhNmMwMTBkN2NiL3AwMDEucG5n",
      "thumbSrc": "https://imgproxy.kitesheet.com/ZV3xMH4SaNm8lSRbLUZF3X3jb47azX1SLH_NeSMRWSA/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82ZDM1NDVhNmMwMTBkN2NiL3AwMDEuanBn",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/zAkGtsJHsa5t6KhWYCtF3UEaBqrLBI1PU1YE68amrSE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy82ZDM1NDVhNmMwMTBkN2NiL3AwMDEucG5n"
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 2,
      "slideType": "disclaimer",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/2",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 3,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": "The slide uses a list of callout boxes to highlight key company milestones and financial status.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/3",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-3",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 4,
      "slideType": "roadmap",
      "function": "present_solution",
      "notes": "The slide uses a timeline-based visualization to show the status of drug development programs.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/4",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-4",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 5,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/5",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-5",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 6,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a horizontal process-like flow to present key metrics.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/6",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-6",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 7,
      "slideType": "other",
      "function": "present_solution",
      "notes": "The slide emphasizes the bioerodible nature and small size of the insert compared to legacy technology.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/7",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-7",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 8,
      "slideType": "other",
      "function": "present_solution",
      "notes": "The slide explains the mechanism of action (Vorolanib) and the delivery technology (Durasert E) for the product DURAVYU.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/8",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-8",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 9,
      "slideType": "case_study",
      "function": "illustrate_case",
      "notes": "The slide uses a table-like structure to map clinical trials (DAVIO, DAVIO 2, PAVIA, VERONA) to patient counts and key outcomes.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/9",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-9",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 10,
      "slideType": "cover",
      "function": "front_matter",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/10",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-10",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 11,
      "slideType": "business_case",
      "function": "present_solution",
      "notes": "The slide uses a four-column layout to present strategic advantages.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/11",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-11",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 12,
      "slideType": "data_table",
      "function": "quantify_impact",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/12",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-12",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 13,
      "slideType": "timeline",
      "function": "present_framework",
      "notes": "Includes a callout box regarding LUGANO enrollment status.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/13",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-13",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 14,
      "slideType": "timeline",
      "function": "summarize",
      "notes": "The slide uses a timeline framework to track trial progress from Jan 2025 to mid-2026.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/14",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-14",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 15,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "Includes company logo and copyright information.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/15",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-15",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 16,
      "slideType": "comparison_table",
      "function": "compare_options",
      "notes": "The slide uses a timeline-based visual to contrast injection frequency across five different pharmaceutical products.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/16",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-16",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 17,
      "slideType": "case_study",
      "function": "illustrate_case",
      "notes": "The slide uses a timeline-based study design framework.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/17",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-17",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 18,
      "slideType": "case_study",
      "function": "illustrate_case",
      "notes": "The slide uses a split-layout with a summary/thesis on the left and specific trial results on the right.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/18",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-18",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 19,
      "slideType": "case_study",
      "function": "illustrate_case",
      "notes": "The chart compares DURAVYU 2.7mg, 1.3mg, and aflibercept 2mg. A red box highlights the early improvement at Week 4.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/19",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-19",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 20,
      "slideType": "data_table",
      "function": "quantify_impact",
      "notes": "The outlier patient missed multiple visits, leading to significant vision loss at week 24.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/20",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-20",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 21,
      "slideType": "data_table",
      "function": "quantify_impact",
      "notes": "The chart compares DURAVYU 2.7mg, DURAVYU 1.3mg, and Aflibercept 2mg. The final values at Week 24 are highlighted in a box.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/21",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-21",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 22,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "Includes company logo and copyright/disclaimer footer.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/22",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-22",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 23,
      "slideType": "data_table",
      "function": "quantify_impact",
      "notes": "Supplement-free is defined as patients who did not receive a supplement at any point during the study.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/23",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-23",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 24,
      "slideType": "case_study",
      "function": "illustrate_case",
      "notes": "The slide uses a timeline to show the transition from standard-of-care anti-VEGF injections to the DURAVYU treatment.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/24",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-24",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 25,
      "slideType": "case_study",
      "function": "illustrate_case",
      "notes": "The slide uses a timeline to show prior SOC injections followed by the DURAVYU treatment and subsequent follow-up.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/25",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-25",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 26,
      "slideType": "executive_summary",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/26",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-26",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
      "docSlug": "6d3545a6c010d7cb",
      "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
      "authorId": "GoldmanSachs",
      "authorName": "EyePoint Pharmaceuticals",
      "documentKindSlug": "consulting-deck",
      "documentKindLabel": "Consulting deck",
      "sourceTypeSlug": "equity_research",
      "sourceTypeLabel": "Equity research",
      "presentationDate": null,
      "orientation": "landscape",
      "aspectRatio": 1.778,
      "pageNumber": 27,
      "slideType": "other",
      "function": "establish_context",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/27",
      "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
      "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-27",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}